Emerging Trends to Drive Neutralizing Antibody Market Growth at 11.7% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Neutralizing Antibody Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a significant expansion in the size of the neutralizing antibody market. The market, which was valued at $230.25 billion in 2024, is expected to increase to $257.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This increase during the historic period is due to several factors. These include an increase in biologics approvals, more funding being allocated to antibody research, the growing incidence of chronic viral infections, greater awareness of immunotherapy, and an increase in healthcare expenditure.

How Will the Neutralizing Antibody Market Size Evolve and Grow by 2029?
The market size for neutralizing antibodies is predicted to experience significant expansion in the coming years, with projections indicating that it may reach $401.16 billion in 2029, growing at a compound annual growth rate (CAGR) of 11.7%. This anticipated growth over the forecast period could be due to an upsurge in emerging infectious diseases, an increase in autoimmune disorders, a burgeoning pipeline of antibody-centric therapies, increased need for precision medicine, and a mounting demand for targeted treatments. The key trends foreseen for this period include a shift towards bispecific and multispecific antibodies, the incorporation of artificial intelligence (AI) in antibody discovery, development of antibody-drug conjugates, an increased utilization of plant-based antibody production, and a rise in custom immunotherapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

What Drivers Are Propelling the Growth of Neutralizing Antibody Market Forward?
The escalation in infectious diseases' occurrence is anticipated to boost the neutralizing antibody market's expansion. The term infectious diseases denote ailments provoked by harmful pathogens like bacteria, viruses, fungi or parasites, which can transmit directly or indirectly from one individual to another. The increased travel activities are intensifying the prevalence of these diseases by permitting the swift transmission of pathogens beyond borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically pinpointing and obstructing pathogens, thus proving effective in preventing deterioration of diseases. They enhance patient results by delivering precise and immediate immune protection. For example, the UK Health Security Agency, a government agency based in the UK, reported in February 2024 that tuberculosis (an infectious bacterial infection that predominantly impacts the lungs) cases in England inflated to 4,850 in 2023, a surge of 10.7% from 4,380 cases in 2022. Hence, the escalation in the occurrence of infectious diseases is fueling growth in the neutralizing antibody market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Which Emerging Trends Are Transforming the Neutralizing Antibody Market in 2025?
Key players in the neutralizing antibody market are concentrating on the creation of cutting-edge therapies such as targeted treatments. These treatments aim to tackle infectious diseases by methodically neutralizing viruses and inhibiting them from entering human cells. Targeted treatments specifically focus on molecular markers or pathways that aid in the growth and sustenance of disease-causing cells like those in cancer or viruses. An example of this occurred in February 2022 when Eli Lilly and Company, a pharmaceutical corporation based in the United States, received Emergency Use Authorization from the U.S. Food and Drug Administration for Bebtelovimab. This is a neutralizing monoclonal antibody therapy directed towards COVID-19. Bebtelovimab is set to treat patients with high risk of advancing to severe states of COVID-19, including hospitalization and death, by treating their mild to moderate symptoms. This approval facilitates prompt treatment amongst arising viral variants, aiding in efforts to lessen the severity of the disease and enhance patient outcomes.

What Are the Key Segments in the Neutralizing Antibody Market?
The neutralizing antibody market covered in this report is segmented -

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies
2) By Target Virus: SARS-CoV-2 (COVID-19), Human Immunodeficiency Viruses (HIV), Influenza, Ebola, Zika, Hepatitis C, Other Target Viruses
3) By Distribution Channel: Direct Sales To End-Users, Distributors, Online Retail, Other Distribution Channels
4) By Application: Therapeutics, Diagnostics, Research And Development
5) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Other End Users

Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies
2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies, Recombinant Polyclonal Antibodies, Human Polyclonal Antibody Preparations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24620&type=smp

Who Are the Key Players Shaping the Neutralizing Antibody Market's Competitive Landscape?
Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

What Geographic Markets Are Powering Growth in the Neutralizing Antibody Market?
North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24620

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.